Research highlighted the pivotal role of P2RX7 in driving inflammatory and fibrotic processes in idiopathic pulmonary fibrosis (IPF). The research suggests that adenosine triphosphate (ATP), an ...

AI models suggest IPF is a dysregulation of aging, not just accelerated aging, with unique gene expression patterns. Key pathways in IPF and aging include TGF-β signaling, oxidative stress, ...

Project Leader: Steven Duncan, M.D. Idiopathic pulmonary fibrosis (IPF) is a morbid fibroproliferative lung disease of older adults that causes progressive dyspnea and hypoxemia. Current treatments ...

GRI Bio on track to launch Phase 2a biomarker study for lead program, GRI-0621 a type 1 invariant NKT (iNKT) antagonist for the treatment of IPF before year end LA JOLLA, CA, Oct. 19, 2023 (GLOBE ...

Please provide your email address to receive an email when new articles are posted on . Rentosertib was shown to be safe in a 12-week phase 2a trial in China. Two doses improved FVC vs. placebo.

“Our findings establish novel connections between aging biology and IPF pathogenesis while demonstrating the potential of AI-guided approaches in therapeutic development for age-related diseases.” ...

Dysregulated bidirectional epithelial–mesenchymal crosstalk: A core determinant of lung fibrosis progression Understanding the cause of the lung scarring can lead to the development of biomarkers and ...

Researchers from Shanghai Jiao Tong University and affiliated organizations have published their findings from studies that aimed to investigate the pathogenesis of idiopathic pulmonary fibrosis (IPF) ...

Findings demonstrate that the number of NKT cells positively correlates with the number of airway macrophages in IPF patients GRI Bio on track to launch Phase 2a biomarker study for lead program, ...